How Does Hemgenix Work? Mechanism of Action Explained in Plain English

Hemgenix (etranacogene dezaparvovec-drlb) is not a medication in the traditional sense. It doesn't need to be taken daily, weekly, or even annually. Instead, it works by delivering a working copy of the gene that hemophilia B patients are missing — potentially enabling the body to produce its own clotting Factor IX for years after a single infusion.

Here is a plain-English explanation of how Hemgenix works, from the moment it enters your body to the weeks and months after infusion.

The Root Cause of Hemophilia B

Hemophilia B is caused by a mutation in the F9 gene — the gene that carries the instructions for making Factor IX, a protein your liver produces to help blood clot. Without enough Factor IX, even minor injuries can cause prolonged or dangerous bleeding. The condition is X-linked, meaning it primarily affects males (who have one X chromosome and no backup copy of the gene).

Traditional Factor IX replacement therapies work by infusing Factor IX protein directly into the bloodstream — temporarily bringing levels up to a safe range. But because Factor IX has a limited lifespan in the body, infusions must be repeated 2–3 times per week indefinitely. Gene therapy takes a fundamentally different approach: instead of delivering the protein, it delivers the gene instructions.

Step 1: The AAV5 Viral Vector — A Molecular Delivery Truck

Hemgenix uses an adeno-associated virus serotype 5 (AAV5) as its delivery vehicle — often called a "vector." AAV5 is a naturally occurring, non-disease-causing virus that has been engineered in the laboratory to carry a payload: the corrected F9 gene. The virus itself has been stripped of its ability to replicate or cause infection. It is essentially a molecular delivery truck.

AAV5 was specifically chosen for Hemgenix because:

It naturally targets liver cells (hepatocytes), which is exactly where Factor IX is made in the body

Pre-clinical and clinical data show AAV5-based therapies can work even in patients with pre-existing antibodies to the virus, potentially increasing eligibility compared to other AAV serotypes

AAV5 has an established safety track record across multiple clinical trials with no confirmed cytotoxic T-cell responses to the capsid protein

Step 2: The Padua Variant — A High-Activity F9 Gene

The gene delivered by Hemgenix is not just any copy of the F9 gene — it is a specially optimized version called the Padua variant (hFIX598 Padua). The Padua variant was first identified in a patient with unusually high Factor IX activity and encodes a form of Factor IX that is approximately 8 times more active than the standard wildtype protein. This allows Hemgenix to achieve near-normal clotting factor levels even without delivering the same total amount of protein as standard replacement therapy.

The gene is also "codon-optimized" — meaning the DNA sequence has been edited to allow liver cells to produce the protein as efficiently as possible. A liver-specific promoter is included to ensure the gene is only expressed (turned on) in liver cells, not elsewhere in the body.

Step 3: After Infusion — The Gene Reaches the Liver

When Hemgenix is infused intravenously, the AAV5 vectors travel through the bloodstream to the liver. The liver naturally filters blood, allowing the AAV5 particles to enter hepatocytes (liver cells). Once inside, the AAV5 releases the F9 gene payload, which remains in the cell nucleus.

Importantly, the delivered F9 gene primarily exists as an episome — it stays outside the cell's chromosomes rather than inserting into DNA, reducing the risk of disrupting existing genes. However, some integration into the genome does occur at low levels, which is the basis for the theoretical (but unproven, as of 2026) risk of hepatocellular carcinoma in the long term.

Step 4: Factor IX Production Begins

Once the F9 Padua gene is inside the hepatocytes, the cell's own machinery reads the gene instructions and begins producing Factor IX protein. It may take several weeks before meaningful Factor IX levels are achieved — patients should continue their existing Factor IX prophylaxis during this ramp-up period.

In the HOPE-B trial, mean Factor IX activity reached 39.0 IU/dL at 6 months post-infusion. Over 5 years of follow-up, levels have remained stable in most patients — demonstrating the long-term durability of this approach.

Why the Immune System Can Complicate Things

The most clinically significant post-infusion challenge is immune-mediated hepatotoxicity. After the AAV5 vector enters liver cells, the immune system may recognize viral capsid proteins on the surface of transduced hepatocytes and mount an attack. This immune response can cause liver enzyme elevations (elevated ALT and AST) and can also potentially reduce Factor IX production by damaging the very cells that now carry the gene.

This is why weekly liver function monitoring for 3 months (then monthly up to 1 year) is required — and why corticosteroids are used if liver enzymes rise above normal levels. Avoiding alcohol and hepatotoxic supplements during the first year is strongly recommended.

For detailed information about side effects and monitoring requirements, see Hemgenix Side Effects: What to Expect and When to Call Your Doctor. If you need help finding a certified center with Hemgenix in stock near you, visit medfinder.com.